148 related articles for article (PubMed ID: 35771033)
21. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
[TBL] [Abstract][Full Text] [Related]
22. Modification of uptake and antiproliferative effect of methylglyoxal bis(guanylhydrazone) by treatment with alpha-difluoromethylornithine in rodent cell lines with different sensitivities to methylglyoxal bis(guanylhydrazone).
Alhonen-Hongisto L; Levin VA; Marton LJ
Cancer Res; 1985 Feb; 45(2):509-14. PubMed ID: 3917847
[TBL] [Abstract][Full Text] [Related]
23. Effects of DFMO-induced polyamine depletion on human tumor cell sensitivity to antineoplastic DNA-crosslinking drugs.
Seidenfeld J; Komar KA; Naujokas MF; Block AL
Cancer Chemother Pharmacol; 1986; 17(1):16-20. PubMed ID: 3084110
[TBL] [Abstract][Full Text] [Related]
24. Effects of DL-alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, on the rat mammary tumour induced by 7,12-dimethylbenz[a]anthracene.
Fozard JR; Prakash NJ
Naunyn Schmiedebergs Arch Pharmacol; 1982 Jul; 320(1):72-7. PubMed ID: 6811956
[TBL] [Abstract][Full Text] [Related]
25. Alpha-difluoromethylornithine-resistant cell lines obtained after one-step selection of Leishmania mexicana promastigote cultures.
Sánchez CP; Mucci J; González NS; Ochoa A; Zakin MM; Algranati ID
Biochem J; 1997 Jun; 324 ( Pt 3)(Pt 3):847-53. PubMed ID: 9210409
[TBL] [Abstract][Full Text] [Related]
26. Growth inhibition of pathogenic yeast isolates by alpha-difluoromethylornithine: an inhibition of ornithine decarboxylase.
Pfaller MA; Gerarden T; Riley J
Mycopathologia; 1987 Apr; 98(1):3-8. PubMed ID: 3108666
[TBL] [Abstract][Full Text] [Related]
27. Isolation and characterization of human breast adenocarcinoma cells made resistant to alpha-difluoromethylornithine.
Das B; Vig M; Khurana KK; Madhubala R
Cancer Invest; 2000; 18(2):115-22. PubMed ID: 10705873
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of lupus nephritis in MRL-lpr/lpr mice by inhibiting ornithine decarboxylase.
Gunnia UB; Amenta PS; Seibold JR; Thomas TJ
Kidney Int; 1991 May; 39(5):882-90. PubMed ID: 2067204
[TBL] [Abstract][Full Text] [Related]
29. Ornithine decarboxylase activity in rabbit retina following treatment with alpha-difluoromethylornithine.
Wong CG; Naripthaphan P; Renardel de Lavalette V
Biochem Pharmacol; 1987 Dec; 36(24):4325-9. PubMed ID: 3120737
[TBL] [Abstract][Full Text] [Related]
30. Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.
Merali S; Clarkson AB
Antimicrob Agents Chemother; 1996 Apr; 40(4):973-8. PubMed ID: 8849262
[TBL] [Abstract][Full Text] [Related]
31. Effects of the irreversible ornithine decarboxylase inhibitor, alpha-difluoromethylornithine, aflatoxin B1, and choline deficiency on hepatocarcinogenesis.
Sondergaard D; Taylor F; Newberne PM
Toxicol Pathol; 1985; 13(1):36-49. PubMed ID: 2412277
[TBL] [Abstract][Full Text] [Related]
32. Implication of ornithine decarboxylase and polyamines in pancreatic growth of neonatal rats.
Morisset J; Grondin G
Pancreas; 1987; 2(3):303-11. PubMed ID: 3114741
[TBL] [Abstract][Full Text] [Related]
33. Development of Red-Emissive Carbon Dots for Bioimaging through a Building Block Approach: Fundamental and Applied Studies.
Mintz KJ; Cilingir EK; Nagaro G; Paudyal S; Zhou Y; Khadka D; Huang S; Graham RM; Leblanc RM
Bioconjug Chem; 2022 Jan; 33(1):226-237. PubMed ID: 34914353
[TBL] [Abstract][Full Text] [Related]
34. Biochemical changes associated with alpha-difluoromethylornithine uptake and resistance in Trypanosoma brucei.
Bellofatto V; Fairlamb AH; Henderson GB; Cross GA
Mol Biochem Parasitol; 1987 Oct; 25(3):227-38. PubMed ID: 3122042
[TBL] [Abstract][Full Text] [Related]
35. Impairment of macrophage function by inhibitors of ornithine decarboxylase activity.
Kierszenbaum F; Wirth JJ; McCann PP; Sjoerdsma A
Infect Immun; 1987 Oct; 55(10):2461-4. PubMed ID: 3115898
[TBL] [Abstract][Full Text] [Related]
36. The effect of alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on mitogen-induced interleukin 2 production.
Bowlin TL; McKown BJ; Sunkara PS
Immunopharmacology; 1987 Apr; 13(2):143-7. PubMed ID: 3110101
[TBL] [Abstract][Full Text] [Related]
37. Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent.
Raul F
Biochem Soc Trans; 2007 Apr; 35(Pt 2):353-5. PubMed ID: 17371277
[TBL] [Abstract][Full Text] [Related]
38. Reduced tissue ornithine increases the cytotoxicity of difluoromethylornithine.
Grossie VB; Nishioka K
Anticancer Res; 1996; 16(6B):3731-5. PubMed ID: 9042249
[TBL] [Abstract][Full Text] [Related]
39. Thymoquinone and Difluoromethylornithine (DFMO) Synergistically Induce Apoptosis of Human Acute T Lymphoblastic Leukemia Jurkat Cells Through the Modulation of Epigenetic Pathways.
Alhosin M; Razvi SSI; Sheikh RA; Khan JA; Zamzami MA; Choudhry H
Technol Cancer Res Treat; 2020; 19():1533033820947489. PubMed ID: 32912061
[TBL] [Abstract][Full Text] [Related]
40. Schedule dependent potentiation of antitumor drug effects by alpha-difluoromethylornithine in human gastric carcinoma cells in vitro.
Barranco SC; Townsend CM; Ho BY; Reumont KJ; Koester SK; Ford PJ
Invest New Drugs; 1990; 8 Suppl 1():S9-18. PubMed ID: 1696247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
